asianprimenews
Breaking News
Breaking NewsGeneralPublic Interest

Main Ladega trailer: Akash Pratap Singh brings an emotional yet inspirational story about triumph over trauma

by asianprimenews0539

Akash Pratap Singh’s upcoming film Main Ladega has been communicating an important subject of domestic violence and a scarred childhood. With its poster too, the visual appeal was a strong one and now the film’s trailer has been released. Once again the trailer is so well shot that it beautifully captures the essence of its subject.

Bringing the story of a boy who has seen a scarred childhood, a son who has been helpless seeing his mother endure domestic violence, Akash channelizes his anger into becoming a boxer. He emerges to be one, but the trailer also leaves you asking, why does he want to become a boxer? What is his ulterior motive? Akash’s performance looks so brilliant, though we see a storm brewing inside him, there is also a sense of vulnerability that comes across. The guy who does boxing is as far away from boxing as anyone can be, yet we get to seen an amazing transformation, two completely opposite sides. What is baffling further is to see how it is the same guy who was so not like a boxer, had a lanky physique, goes on to become a boxing burgeon. As a boxer, one sees Akash with a not giving up spirit, but also wonders if it his past that led him to the boxing ring? Well, all these questions will only get answered on 26th April.

Main Ladega’s story is beautifully told. It is high on emotions and highlights how trauma can be turned into triumph. With it, Akash’s journey in the film is also inspiring.

Produced by Akshay Bhagwanji & Pinakin Bhakta. The lead actor Akash Pratap Singh has also written the story. Main Ladega is directed by Gaurav Rana. Presented as well as produced by Kathaakar Films which was founded by Akshay Bhagwanji and Akash Pratap Singh, Main Ladega will be released in theaters on 26th April 2024.

Share

Related posts

Powerplay Weekend in Rise and Fall: Wall of Doglapan, Family Time, and Shocking Eliminations Redefine Equations

asianprimenews

Why CML Isn’t a Solved Disease—And What Patients in India Need to Know* Over the past two decades, Chronic Myeloid Leukemia (CML) has undergone a transformation—from being a life-threatening condition to one that can be controlled with oral medication. Although survival rates have improved significantly, the idea of CML as a ‘manageable’ disease is now being questioned. Clinicians and patients alike are recognizing that the existing standard of care does not address the full picture—especially for India’s younger patient population, whose needs go far beyond survival. Dr Subhaprakash Sanyal Director of Haematology and BMT Services, Fortis Hospital, Mumbai, said, “There’s a common belief that starting treatment for CML means the journey is simple, but that isn’t the case. Many patients struggle to reach their treatment milestones as expected, and a significant portion need to change or stop their medication due to side effects or intolerance. In fact, about 30 to 40% discontinue their initial therapy within five years, highlighting that the standard approach doesn’t work for everyone.” CML disproportionately affects younger adults in India, where the median age of diagnosis is between 35 and 40 years—much younger than the average age of 50–60 in Western countries. At this life stage, patients are often building careers, supporting families, and planning long-term futures. In this context, treatment is no longer just about survival—it’s about maintaining energy, emotional well-being, professional productivity, and daily independence. Historically, the primary treatment goal in CML was achieving Major Molecular Response (MMR). But over the years, these goals have evolved. Today, physicians aim for deeper responses, particularly Deep Molecular Response (DMR). Achieving DMR paves the way for Treatment-Free Remission (TFR), where patients can potentially stop therapy altogether and remain in remission under medical supervision. These advanced milestones are particularly relevant to newly diagnosed patients, as reaching DMR within the first two years greatly improves the likelihood of achieving TFR down the line. Why So Many Patients Fall Short Despite clear treatment goals, a significant proportion fail to achieve MMR within the first year, and even fewer reach DMR by year two. One of the primary reasons is the impact of persistent, low-grade side effects—such as fatigue, joint pain, and gastrointestinal issues—which patients often tolerate silently but which meaningfully reduce their quality of life. These side effects also drive nonadherence, dose modifications, and ultimately treatment discontinuation. In fact, treatment intolerance is the leading cause of therapy discontinuation in the first two years of CML management. Adding to the complexity, current treatments—particularly ATP-competitive tyrosine kinase inhibitors (TKIs)—can affect not just the intended target but also unrelated biological pathways, causing off-target toxicity. This often leads to therapy switches, a strategy that increases both clinical and emotional burden without necessarily resolving the issue. A recent Indian analysis noted that nearly all CML patients report some form of low-grade side effect, many of which disrupt work and personal life but don’t qualify for hospitalization. As a result, patients feel caught in a difficult balance—managing a chronic illness while enduring ongoing discomfort or disruptions. The Case for Better-Tolerated, More Effective Therapies As the treatment landscape evolves, the need for therapies that not only offer deeper molecular responses but also better tolerability is becoming increasingly clear. Emerging therapies with novel mechanisms of action have begun to change the paradigm by offering comparable—or even superior—efficacy alongside fewer adverse events and lower discontinuation rates. In one international phase III trial, a newer therapy demonstrated a 74.1% MMR rate at 96 weeks, significantly higher than the 52.0% achieved by older therapies. It also showed a 54% lower risk of treatment discontinuation due to side effects, while nearly half of patients achieved MR4 and 30.9% achieved MR4.5, the deepest levels of response. These findings suggest that treatment no longer needs to be a trade-off between efficacy and day-to-day functioning. This shift is particularly important in the Indian context, where younger patients face the possibility of decades-long treatment. For them, the ability to tolerate therapy comfortably while still achieving long-term disease control is not a luxury—it’s a necessity. The Importance of Proactive Conversations Many patients continue older treatments unaware that newer, more tolerable options exist. This makes open doctor–patient conversations crucial—especially early in treatment. Patients should understand their goals, like DMR or TFR, and how their therapy aligns with them. Discussing side effects, lifestyle impact, and alternatives helps ensure care is not just effective, but sustainable and suited to their lives. While CML outcomes have improved, challenges remain—particularly for India’s younger patients. As treatment goals expand and better options emerge, the focus must shift from merely managing the disease to helping patients live well. The future of CML care lies in deeper responses, better tolerability, and enabling life beyond medication.

asianprimenews

Anaptyss Scales India GCC Infrastructure to Over 100,000 Sq. Ft. to Scale Global Delivery

asianprimenews